Table 2 Baseline to week 12 endpoint changes in EORTC QLQ-C30 scores by age groups
Ipilimumab plus gp100 | Ipilimumab plus gp100 | Ipilimumab Alone | Ipilimumab Alone | |
|---|---|---|---|---|
< 65 years | ≥ 65 years | < 65 years | ≥ 65 years | |
(N = 170) | (N = 66) | (N = 59) | (N = 26) | |
Physical function | −6.2 | −9.5 | −4.3 | −9.3 |
Role function | −9.8 | −11.7 | −11 | −12.9 |
Emotional function | −0.8 | −6.2 | −2.2 | −9.3 |
Cognitive function | −3.9 | −4.7 | −3.6 | −8.8 |
Social function | −5.4 | −7.4 | −6 | −12.3 |
Global health | −6.5 | −12.1 | −6 | −17 |
Fatigue | 9 | 14.2 | 12.4 | 12.1 |
Nausea/vomiting | 5.3 | 7.3 | 4.9 | 3.1 |
Pain | 7.2 | 6.4 | 10 | 7.4 |
Dyspnea | 2 | 8.1 | 2.1 | 12.5 |
Sleep disturbance | 5 | 10.4 | 8.8 | 12.9 |
Appetite loss | 9.4 | 9.6 | 12.9 | 11.7 |
Constipation | 3.8 | 6 | 2.3 | −0.4 |
Diarrhea | 6.2 | 7.7 | 7.7 | 13.5 |